The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study

PURPOSE: Long-term survival benefit of anthracyclines for human epidermal growth factor receptor 2 (HER2)-positive breast cancer is clear. In the neoadjuvant treatment, compared with the monoclonal antibody such as trastuzumab and pertuzumab, the clinical benefit of pyrotinib, a new small-molecule t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fu, Liang, Yimin, Luo, Ming, Shen, Jiayue, Zhou, Taosheng, Liang, Yajing, Tang, Xiaoqi, Yuan, Huiming, Zeng, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922885/
https://www.ncbi.nlm.nih.gov/pubmed/36793595
http://dx.doi.org/10.3389/fonc.2023.1041111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922885/
https://www.ncbi.nlm.nih.gov/pubmed/36793595
http://dx.doi.org/10.3389/fonc.2023.1041111

Ejemplares similares